Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities (2017 - 2025)

Northwest Biotherapeutics' Preferred Stock Liabilities history spans 8 years, with the latest figure at $12.7 million for Q4 2025.

  • Quarterly results put Preferred Stock Liabilities at $12.7 million for Q4 2025, down 18.04% from a year ago — trailing twelve months through Dec 2025 was $12.7 million (down 18.04% YoY), and the annual figure for FY2025 was $12.7 million, down 18.04%.
  • Preferred Stock Liabilities for Q4 2025 was $12.7 million at Northwest Biotherapeutics, down from $13.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $27.7 million in Q3 2023 to a low of $12.7 million in Q4 2025.
  • The 4-year median for Preferred Stock Liabilities is $17.3 million (2023), against an average of $18.3 million.
  • The sharpest move saw Preferred Stock Liabilities surged 101.27% in 2023, then tumbled 42.61% in 2024.
  • Year by year, Preferred Stock Liabilities stood at $23.1 million in 2022, then fell by 18.83% to $18.7 million in 2023, then fell by 17.15% to $15.5 million in 2024, then fell by 18.04% to $12.7 million in 2025.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $12.7 million, $13.4 million, and $13.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.